HANSA BIOPHARMA

Q4 and Full Year Results Conference Call

February 6, 2025

Forward-looking statements

This presentation may contain certain forward-looking statements and forecasts based on our current expectations and beliefs regarding future events and are subject to significant uncertainties and risks since they relate to events and depend on circumstances that will occur in the future. Some of these forward-looking statements, by their nature, could have an impact on Hansa Biopharma's business, financial condition and results of operations [or that of its parent, affiliate, or subsidiary companies]. Terms such as "anticipates", "assumes", "believes", "can", "could", "estimates", "expects", "forecasts", "intends", "may", "might", "plans", "should", "projects", "will", "would" or, in each case, their negative, or other variations or comparable terminology are used to identify forward-looking statements. There are a number of factors that could cause actual results and developments to differ materially from those projected, whether expressly or impliedly, in a forward-looking statement or affect the extent to which a particular projection is realized. Such factors may include, but are not limited to, changes in implementation of Hansa Biopharma's strategy and its ability to further grow; risks and uncertainties associated with the development and/or approval of Hansa Biopharma's product candidates; ongoing clinical trials and expected trial results; the ability to commercialize imlifidase if approved; changes in legal or regulatory frameworks, requirements, or standards; technology changes and new products in Hansa Biopharma's potential market and industry; the ability to develop new products and enhance existing products; the impact of competition, changes in general economy and industry conditions and legislative, regulatory and political factors.

The factors set forth above are not exhaustive and additional factors could adversely affect our business and financial performance. We operate in a very competitive and rapidly changing environment, and it is not possible to predict all factors, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. Given these risks and uncertainties, investors should not place undue reliance on forward-looking statements as a prediction of actual results.

Hansa Biopharma expressly disclaims any obligation to update or revise any forward-looking statements to reflect changes in underlying assumptions or factors, new information, future events or otherwise, and disclaims any express or implied representations or warranties that may arise from any forward-looking statements. You should not rely upon these forward-looking statements after the date of this presentation.

Q4 and Full Year Results Conference Call Agenda

6 February 2025

CEO Remarks	Søren Tulstrup Chief Executive Officer, President
Operational Update	Søren Tulstrup Chief Executive Officer, President
Pipeline Update	Hitto Kaufmann Chief R&D Officer
Financial Results	Evan Ballantyne Chief Financial Officer
Q&A and Close	Søren Tulstrup Chief Executive Officer, President

Strong full year 2024 IDEFIRIX sales performance

Full Year 2024 Performance

		Including Provision
FY Sales Revenue	189.7 MSEK	140.1 MSEK
FY Total Revenue	220.9 MSEK	171.3 MSEK

Q4 2024 Performance

		Including Provision
Q4 Sales Revenue	25.6 MSEK	- - - - - - - -
Q4 Total Revenue	32.3 MSEK	- - - - - - - -

High Double-digit Revenue Growth

(vs prior year)

- ✓ ***83%*** increase in FY Sales
- ✓ ***35%*** increase in IDEFIRIX sales
- ✓ **28%** increase in FY Total Revenue

Quarterly performance remains solid despite continued fluctuation in organ allocation system

Quarter on Quarter Performance TTM



Quarter on Quarter Performance TTM

**including provision*



TTM: trailing 12 month

Significant pipeline progress in 2024

Key Trial Progress

ConfIdeS Ph 3 (kidney transplant)
Enrolment complete data read out 2H 2025

PAES Ph 3 (kidney transplant)
96% enrolled complete enrolment 2025

GOOD-IDES-02 Ph 3 (anti-GBM)
Enrolment complete data read out 2025

15-HMedIdeS-09 Ph 3 (GBS)
Positive study and indirect treatment comparison results

GNT-018-IDES Ph 2 (gene therapy)
Trial initiated in Crigler-Najjar syndrome

NICE-01 Ph 1 (first in human)
Reg Agency development pathway alignment 2025

SRP-9001-104 Ph 1b (gene therapy)
Enrolment ongoing in DMD

Publications & Presentations

17-HMedIdes-14 (kidney transplant)
- ✓ Presented at AST
- ✓ Published in AJT
- ✓ Presented at SITO

16-HMedIdes-12 Ph 2 (AMR)
- ✓ Published in *Clinical Transplantation* (July)

RWE Data (kidney transplant)
- ✓ Published in *KI Report*
- ✓ Presented at AST

IDEFIRIX EU launch remains on track

Clinical Readiness

114 clinics are IDEFIRIX ready to treat

36 centers with clinical experience
(3 additional markets in Q4)

66% of clinics in 11 markets have repeat use

Patient Selection & Treatment

282 local scientific events and KOL engagement

7 countries issued clinical guidelines

2 international consensus / guidance on desensitization **NEW international consensus on imlifidase published in Transplant International*

Market Access

Reimbursement in 18 markets incl. largest EU markets
**3 additional markets in Jan 2025*

Access in 75% of EU transplant market

Q4 and Full Year 2024 Results Conference

6 February 2025

CEO Remarks	Søren Tulstrup Chief Executive Officer, President
Operational Update	Søren Tulstrup Chief Executive Officer, President
Pipeline Update	**Hitto Kaufmann** **Chief R&D Officer**
Financial Results	Evan Ballantyne Chief Financial Officer
Q&A and Close	Søren Tulstrup Chief Executive Officer, President

Broad clinical pipeline



	Preclinical	Phase 1	Phase 2	Phase 3	Marketing authorization	Marketed	Partner	Status	Next anticipated milestone
Imlifidase									
EU: Kidney transplantation in highly sensitized patients[1,2]								Commercialization ongoing Post approval Clinical Phase 3 ongoing	EU: Additional agreements around reimbursement / Post authorization study to be completed by end of 2025
U.S. "ConfIdeS": Kidney transplantation in highly sensitized patients[1,2]								Clinical Phase 3 ongoing	Data readout in 2H 2025
GOOD-IDES-02: Anti-GBM antibody disease								Clinical Phase 3 ongoing	Data readout in 2025
16-HMedIdes-12: Active Antibody Mediated Rejection (AMR)								Clinical Phase 2 completed	
15-HMedIdeS-09: Guillain-Barré Syndrome (GBS)								Clinical Phase 2 completed	Publication in peer-reviewed journal Preparation of Phase 3 trial
Investigator-initiated trial in ANCA-associated vasculitis[3]								Clinical Phase 2 ongoing	Complete enrollment (10 patients)
SRP-9001-104: Pre-treatment ahead of gene therapy in Duchenne Muscular Dystrophy (DMD)							SAREPTA THERAPEUTICS	Clinical Phase 1b ongoing	Complete enrollment
Pre-treatment ahead of gene therapy in Limb-Girdle Muscular Dystrophy (LGMD)							SAREPTA THERAPEUTICS	Preclinical research ongoing	Preclinical research
Pre-treatment ahead of gene therapy in Pompe disease							AskBio	Preclinical research ongoing	Preclinical research
Pre-treatment ahead of gene therapy in Crigler-Najjar syndrome							GENETHON CURE THROUGH INNOVATION	Clinical Phase 2 ongoing	Complete enrollment
HNSA-5487									
NICE-01: HNSA-5487 – Lead candidate from the NiceR program								Clinical Phase 1 completed	Alignment with regulatory authorities on clinical development pathway in neuro-autoimmune diseases

[1] Results from the Phase 1 study have been published, Winstedt et al. (2015) PLOS ONE 10(7)
[2] Lorant et al., American Journal of Transplantation and 03+04 studies (Jordan et al., New England Journal of Medicine)
[3] Investigator-initiated study by Dr. Adrian Schreiber and Dr. Philipp Enghard, at Charité Universitätsmedizin, Berlin, Germany

Advancing the science in Autoimmune, Gene Therapy, and Transplantation

Delivering the Pipeline

8 Ongoing clinical trials in autoimmune, gene therapy and transplantation

Advancing the Science

10 Publications in peer–reviewed journal

9 Presentations at leading medical congresses

ATC2024 AMERICAN TRANSPLANT CONGRESS PHILADELPHIA, PA • JUNE 1-5

ASGCT American Society of Gene + Cell Therapy

Nephrologie 2024 26.–29.09.2024, Berlin 16. Jahrestagung der Deutschen Gesellschaft für Nephrologie

IMLIFIDASE
IgG cleaving therapy with a unique MOA

AUTOIMMUNE

15-HMedIdeS-09 Ph 2 (GBS)
Indirect Treatment Comparison and
Full data read out COMPLETE

GOOD-IDES-02 Ph 3 (anti-GBM disease)
Enrolment COMPLETE
Data Readout 2H 2025

GENE THERAPY

Sarepta SRP-9001-104 Ph 1b (DMD)
Trial COMMENCED
Data Readout 2025

Genethon GNT-018-IDES Ph 2 (Crigler-Najjar)
Trial COMMENCED

TRANSPLANTATION

US ConfIdeS Ph 3 (kidney)
Enrolment COMPLETE
Data Readout 2H 2025

16-HMedIdeS-12 Ph 2 (AMR)
Trial COMPLETE
Data published July 2024

Post Authorization Efficacy Ph 3 (kidney)
Enrolment ONGOING (96%)
Trial to complete in 2025

HNSA-5487
next-gen IgG cleaving molecule with redosing potential

NICE-01 FIH Ph 1
Trial and 12mth analysis COMPLETE
Alignment with reg agencies on development pathway in 2025

15-HMedIdeS-09 Phase 2 Study demonstrated the role imlifidase may play in halting the progression of GBS

Study Overview

- Open-label, single arm, multi-center study across the UK, France, and the Netherlands. Patients with severe GBS were included (GBS DS ≥ 3)
- Evaluated safety, tolerability, and efficacy of single dose imlifidase (0.25 mg/kg) in combination with IVIg in 27 adult GBS patients

Rapid overall improvement in functional status including expedited muscle recovery

37% of patients able to walk independently at Week 1

67% of patients able to walk independently at Week 8

63% of patients able to run or had no functional disability (GBS DS<1) at 6 months

Administration of imlifidase was overall safe and well tolerated

GBS disability score (DS) is defined as: 0 = Healthy; 1 = Minor symptoms and capable of running; 2 = Able to walk independently 10 meters or more but unable to run; 3 = Able to walk more than 10 meters across an open space with help; 4 = Bedridden or chair bound; 5 = Needing mechanical ventilation; 6 = Dead

Imlifidase in combination with IVIg delivered clinically meaningful benefit to patients with severe GBS

Substantial early improvement in functional status in Phase 2 study
well tolerated/consistent safety profile

Patients treated with imlifidase plus IVIg in Phase 2 study had rapid overall improvement in functional status

Rapid overall improvement in functional status	**37%** returned to walking independently at 1 week
	Median time to independently walking (**16 days**)
	Median time to improve **by at least one** grade on GBS DS (6 days)
	MRC sum score of **10.7 points** at 1 week
4 WEEKS	**33%** regained the ability to run
8 WEEKS	**67%** able to walk independently
	41% regained the ability to run
	37% improved by at least 3 points in GBS DS
6 MONTHS	**63%** able to run or had no functional disability

Significantly faster improvement in clinically meaningful measures vs standard of care IVIg

In comparison to IGOS-IVIg group (n=754), patients experienced significantly faster improvement across clinically relevant measures

Median time to return to independently walking **6 weeks sooner** than IVIg comparator group (p=0.03)

Median time to improvement by at least one grade on GBS DS **3 weeks sooner** (p=0.002)

1 WEEK	**6.4 times** more likely to walk independently (OR 95% CI: 2.3-17.5, p<0.001)
4 WEEKS	**4.2 times** more likely to walk independently (OR 95% CI: 1.6-11.5, p=0.005)

GBS disability score (DS) is defined as: 0 = Healthy; 1 = Minor symptoms and capable of running; 2 = Able to walk independently 10 meters or more but unable to run; 3 = Able to walk more than 10 meters across an open space with help; 4 = Bedridden or chair bound; 5 = Needing mechanical ventilation; 6 = Dead
IGOS – International GBS Outcome Study
OR - odds ratio

Q4 and Full Year 2024 Results Conference

6 February 2025

CEO Remarks	Søren Tulstrup Chief Executive Officer, President
Operational Update	Søren Tulstrup Chief Executive Officer, President
Pipeline Update	Hitto Kaufmann Chief R&D Officer
Financial Results	**Evan Ballantyne** **Chief Financial Officer**
Q&A and Close	Søren Tulstrup Chief Executive Officer, President

Strong full year IDEFIRIX sales performance with double digit growth year on year

Revenue (Q/Q)



*Provision

Revenue (FY/FY)



**From agreements with Sarepta, AskBio & Axis-Shield

Product Sales (Q/Q)



*Provision

Product Sales, Trailing 12 months (TTM)



Continued investments in R&D and commercialization











Cash runway into 2026 through directed share issue in Q2’24









Q4 and Full Year 2024 Results Conference

6 February 2024



CEO Remarks	Søren Tulstrup Chief Executive Officer, President
Pipeline Update	Hitto Kaufmann Chief R&D Officer
Financial Results	Evan Ballantyne Chief Financial Officer
Q&A and Close	**Søren Tulstrup** **Chief Executive Officer, President**

HANSA BIOPHARMA LEADERSHIP

Søren Tulstrup

President & CEO

Hitto Kaufmann

Chief R&D Officer

Evan Ballantyne

CFO

Hansa Biopharma contacts and key events

Contacts

Evan Ballantyne

Chief Financial Officer

Email: ir@hansabiopharma.com

Stephanie Kenney

VP, Corporate Affairs

E-mail: media@hansabiopharma.com

Calendar and events

2025

21 MAR	Annual & Sustainability Report 2024
17 APR	Q1 2025 (January – March) Report
17 JULY	Q2 2025 (January – June) Report


HANSA®
BIOPHARMA